It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Background
Vaccination against human papillomavirus (HPV) represents a critical strategy in the global effort to eradicate cervical cancer. Nonetheless, the uptake of HPV vaccination in Cameroon has been slow, resulting in vaccine wastage during a period of constrained global supply. In the Saa health district, factors such as concerns about infertility, fears of COVID-19 infection, and restrictions on HPV awareness initiatives in Catholic churches and schools have been identified as contributors to vaccine hesitancy. This report outlines the observations from a successful impromptu HPV vaccination campaign conducted in the context of this hesitancy within the Saa health district.
Methods
The campaign took place from the 9th to 25th of May 2023 and targeted 853 adolescents aged 9–13 years. A single-dose schedule with Gardasil was used mainly through the school strategy. Community health workers, teachers and priests participated in sensitization activities via door-to-door sensitization for parents, sensitization in schools for students and in churches for faithfuls respectively. Health facilities vaccinated schools in their catchment area. Vaccination data were recorded in routine vaccination registers.
Results
A total of 1321 adolescents (154%) were vaccinated, 48.9% (n = 646) of whom were boys. Thirty-four primary and two secondary schools participated in the campaign. Health workers, teachers and Catholic priests all participated in sensitization activities. No backlash was reported from parents after vaccination.
Conclusion
The successful execution of the campaign can be attributed to the active involvement of key stakeholders within the health district. Continuous advocacy for HPV vaccination, even in a climate of vaccine hesitancy, plays a significant role in positively altering perceptions. Recognizing stakeholders and their influence is essential for tailoring strategies aimed at enhancing HPV vaccine uptake.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer